scholarly journals Drug-coated Balloon-only Angioplasty for Native Coronary Disease Instead of Stents

2016 ◽  
Vol 11 (2) ◽  
pp. 110 ◽  
Author(s):  
Upul Wickramarachchi ◽  
Simon Eccleshall ◽  
◽  
Keyword(s):  
De Novo ◽  
Metallic Stent ◽  
Chemotherapeutic Drug ◽  
Absorbable Polymers ◽  
Late Thrombosis ◽  
Artery Disease ◽  
Permanent Implant ◽  
Early Restenosis ◽  
Drug Coated Balloon

Coronary angioplasty has vastly improved both in technique and devices since the first angioplasty in 1977. Currently, stent implantation is used almost ubiquitously, despite being developed originally to treat vessel threatening dissections. Newer concepts including absorbable polymers or fully bioabsorbable scaffolds are constantly being developed. However, we find the concept of no permanent implant whilst still delivering a chemotherapeutic drug to reduce restenosis very attractive given the long term implications of a metallic stent, which include restenosis, late thrombosis and neo-atheroma formation. The use of a drug-coated balloon-only approach to de novo angioplasty will avoid the late thrombotic problems whilst also reducing early restenosis, simplifying the procedure and reducing the dual antiplatelet duration to 1 month. We review the current literature and highlight our practice with regard to use of drug-coated balloons in treatment of de novo coronary artery disease.

scholarly journals Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB study

2020 ◽  
Author(s):  
Ioannis Merinopoulos ◽  
Tharusha Gunawardena ◽  
Upul Wickramarachchi ◽  
Paul Richardson ◽  
Clint Maart ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
De Novo ◽  
Artery Disease ◽  
Drug Coated Balloon

Drug-coated balloon treatment for nonsmall de-novo coronary artery disease

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ae-Young Her ◽  
Song Lin Yuan ◽  
Eun Jung Jun ◽  
Youngjune Bhak ◽  
Moo Hyun Kim ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
De Novo ◽  
Artery Disease ◽  
Drug Coated Balloon

scholarly journals Drug-coated balloon in combination with bare metal stent strategy for de novo coronary artery disease

Medicine ◽  
2017 ◽  
Vol 96 (12) ◽  
pp. e6397 ◽  
Author(s):  
Wenjie Lu ◽  
Yongjian Zhu ◽  
Zhanying Han ◽  
Xi Wang ◽  
Xule Wang ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
De Novo ◽  
Bare Metal Stent ◽  
Bare Metal ◽  
Metal Stent ◽  
Artery Disease ◽  
Drug Coated Balloon

scholarly journals Sex-Related Outcomes of Successful Drug-Coated Balloon Treatment in De Novo Coronary Artery Disease

2021 ◽  
Vol 62 (11) ◽  
pp. 981
Author(s):  
Liu Kun ◽  
Eun-Seok Shin ◽  
Eun Jung Jun ◽  
Youngjune Bhak ◽  
Scot Garg ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
De Novo ◽  
Artery Disease ◽  
Drug Coated Balloon

Risk of Mortality with Paclitaxel Drug-Coated Balloon in De Novo Coronary Artery Disease

2020 ◽  
Vol 21 (4) ◽  
pp. 549-555
Author(s):  
Charan Yerasi ◽  
Brian C. Case ◽  
Brian J. Forrestal ◽  
Paul Kolm ◽  
Kazuhiro Dan ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
De Novo ◽  
Risk Of Mortality ◽  
Artery Disease ◽  
Drug Coated Balloon

Drug-Coated Balloon Angioplasty in Atherosclerosis Patients With Popliteal Artery Involvement

2018 ◽  
Vol 25 (5) ◽  
pp. 581-587 ◽  
Author(s):  
Tomoharu Dohi ◽  
Andrej Schmidt ◽  
Dierk Scheinert ◽  
Yvonne Bausback ◽  
Daijiro Kabata ◽  
...  
Keyword(s):  
Popliteal Artery ◽  
De Novo ◽  
Vessel Diameter ◽  
Primary Patency ◽  
Lesion Length ◽  
Endovascular Interventions ◽  
Long Term Follow Up ◽  
Drug Coated Balloon

Purpose: To investigate outcomes of drug-coated balloon (DCB) angioplasty in endovascular interventions including or restricted to the popliteal artery. Methods: A retrospective analysis was conducted of 266 patients [median age 72 years, interquartile range (IQR) 62, 78; 166 men] treated with DCB angioplasty in 281 de novo lesions including the popliteal artery between December 2011 and January 2015 at a single center. The median lesion length was 270 mm (IQR 150, 373). The study outcomes were primary patency and predictors of restenosis [reported as the hazard ratio (HR) with 95% confidence interval (CI)]. Results: The primary patency was 77.4% at a median 12.2 months (IQR 5.7, 18.8). Independent variables associated with restenosis included baseline Rutherford category (HR 1.36, 95% CI 1.05 to 1.77, p=0.02), reference vessel diameter (HR 0.77, 95% CI 0.63 to 0.95, p=0.02), dissection (HR 1.69, 95% CI 1.022.79, p=0.04), and standard nitinol stent use (HR 2.08, 95% CI 1.14 to 3.79, p=0.02). Conclusion: Outcomes after DCB angioplasty in lesions including the popliteal artery were acceptable compared with previous studies. Further investigation with long-term follow-up is needed to confirm these results.

scholarly journals Drug-Coated Balloon vs. Stent for de novo Non-small Coronary Artery Disease: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Kaiwen Sun ◽  
Zhenzhu Liu ◽  
Hongyan Wang
Keyword(s):  
Systematic Review ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
De Novo ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Significant Difference ◽  
Artery Disease ◽  
Drug Coated Balloon

Introduction: Drug-coated balloon (DCB) has been an attractive option in de novo vessels. A systematic review and meta-analysis were conducted to evaluate the efficacy and safety of DCB vs. stent for treating de novo lesions in non-small vessels.Methods: Studies in PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science were searched (from their commencement to March 2021). This meta-analysis was performed by Review Manager 5.3.Results: A total of 3 random controlled trials (RCTs) with 255 patients and 2 observational studies (OS) with 265 patients were included in this meta-analysis following our inclusion criteria. It could be observed that DCB presented no significant difference in cardiac death (CD) (RR 0.33, 95% CI [0.01, 8.29], p = 0.50 in OS), myocardial infarction (MI) (RR 0.49, 95% CI [0.09, 2.50], p = 0.39 in RCT), target lesion revascularization (TLR) (RR 0.64, 95% CI [0.19, 2.18], p = 0.47 in RCT) (RR 1.72, 95% CI [0.56, 5.26], p = 0.34 in OS), and late lumen loss (LLL) (SMD −0.48, 95% CI [−1.32, 0.36], p = 0.26 in RCT) for de novo non-small coronary artery disease (CAD) compared with stents, whereas minimal lumen diameter (MLD) including MLD1 (SMD −0.67, 95% CI [−0.92 −0.42], p < 0.00001 in RCT) and MLD2 (SMD −0.36, 95% CI [−0.61 −0.11], p = 0.004 in RCT) was smaller in DCB group.Conclusion: This systematic review showed that DCB might provide a promising way on de novo non-small coronary artery disease compared with stents. However, more RCTs are still needed to further prove the benefits of the DCB strategy.Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO/#recordDetails.

Sign in / Sign up

Export Citation Format

Share Document